| Schedule of Segment Information |
| | | | | | | | | | | | | | | Six Months Ended June 30, | | Three Months Ended June 30, | (U.S. dollars in thousands) | | 2026 | | 2025 | | 2026 | | 2025 | Revenues from customers | | $ | 53,646 | | $ | 25,771 | | $ | 19,896 | | $ | 15,658 | Less: | | | | | | | | | | | | | Employee salaries and related expenses | | | 14,352 | | | 10,649 | | | 7,655 | | | 5,444 | Sub-contractors expense | | | 8,340 | | | 7,463 | | | 3,899 | | | 4,773 | Interest expense | | | - | | | - | | | - | | | - | Interest income | | | (848) | | | (528) | | | (660) | | | (272) | Depreciation | | | 810 | | | 706 | | | 406 | | | 360 | R&D grant | | | (2,100) | | | | | | (2,100) | | | | Other segment expenses, net* | | | 7,091 | | | 10,552 | | | 5,836 | | | 4,692 | Income (loss) before taxes on income | | | 26,001 | | | (3,071) | | | 4,860 | | | 661 | Taxes on income | | | 3,907 | | | 384 | | | 1,083 | | | 497 | Segment net income (loss) | | $ | 22,094 | | $ | (3,455) | | $ | 3,777 | | $ | 164 |
* Other expenses included in net income include raw materials, rent, and utilities, and others.
|
| Schedule of Disaggregation of Revenues |
| c. | The following table summarizes the Company’s disaggregation of revenues: |
| | | | | | | | | | | | | | Six Months Ended June 30, | | Three Months Ended June 30, | | (U.S. dollars in thousands) | 2026 | | 2025 | | 2026 | | 2025 | | Gaucher disease: | | | | | | | | | | | | | Pfizer (Ireland) | $ | 5,731 | | $ | 12,626 | | $ | 4,279 | | $ | 5,647 | | Fiocruz (Brazil) | $ | 3,968 | | $ | 3,016 | | $ | 1,514 | | $ | - | | Fabry disease: | | | | | | | | | | | | | Chiesi (Italy) | $ | 17,548 | | $ | 9,793 | | $ | 14,035 | | $ | 9,793 | | Total revenues from selling goods | $ | 27,247 | | $ | 25,435 | | $ | 19,828 | | $ | 15,440 | | Revenues from license and R&D services | $ | 26,399 | | $ | 336 | | $ | 68 | | $ | 218 | |
|